and leaflet malcoaptation. These processes promote leaflet fusion, valve degeneration, and aortic wall remodeling, which ultimately lead to AI (4, 5) . These functional and anatomic changes take their toll over time; 15% of patients will eventually experience moderate to severe AI (5), which can limit the "durability" of LVAD therapy. Sciences Center, Salt Lake City, Utah. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose. with the PCWP suggests that these measures could be used to assess AI severity in cf-LVAD patients, although thresholds for concern remain to be determined.
There are limitations to this work that need to be considered. First, although carefully conducted and prospective, the study involved 20 patients, of whom only 13 had AI. Moreover, regurgitant fraction could not be determined for all of the patients (i.e., 75%).
Second, the exclusive enrollment of HeartMate II LVAD patients limit the extrapolation of these data to patients supported by different devices. In particular, 
